Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.

Herein, UV spectrophotometry assisted by multivariate chemometric analysis have been presented for quantitative determination of complex quinary therapy containing atenolol, ramipril, hydrochlorothiazide, simvastatin and aspirin without any prior separation. Such combination is very useful for treating various cardiovascular diseases (CVD) including high blood pressure, hypercholesterolemia in addition to its antiplatelet aggregating activity. Calibration (15 samples) and validation (10 samples) sets were prepared of different concentrations for these drugs via implementing partial factorial experimental design. The zero order UV spectra of these sets were recorded and then subjected for further chemometric analysis. Partial least square (PLS) with/without variable selection procedure i.e. genetic algorithm (GA) were employed to untangle the UV spectral overlapping of these mixtures. The performance of these chemometric techniques were compared in terms of accuracy and predictive abilities using cross-validation and external validation methods. It was found that PLS provides good recoveries with prompt predictive ability albeit GA-PLS exhibited better analytical performance owing to its capability to remove redundant variables i.e. the number of absorbance variables had been reduced to about 19-28%. The developed methods allowed reliable determination of such complex therapy in its laboratory prepared mixtures and pharmaceutical preparation within comparable results to those reported by HPLC method, posing these chemometric methods as valuable and indispensable analytical tools in in-process testing and quality control analysis of many pharmaceutical compounds targeting CVD.

Utility of 4-chloro-7-nitrobenzofurazan (NBD-CI) for the Spectrophotometric and spectrofluorometric determination of several antihistamine and antihypertensive drugs.

New, sensitive, and selective spectrophotometric and spectrofluorometric methods have been developed for determination of clemastine hydrogen fumarate (Clem), loratadine (Lor), losartan potassium (Los), and ramipril (Ram) in both pure form and pharmaceutical formulations using 4-chloro-7-nitrobenzofurazan (NBD-CI), which is a highly sensitive chromogenic and fluorogenic reagent. The relation between absorbance at 470, 467, 471, and 469 nm and the concentration was linear over the ranges 5-35, 10-100, 10-90, and 10-120 microg/mL for Clem, Lor, Los, and Ram, respectively. The complexation products were also measured spectrofluorometrically at the emission wavelength 535 nm for Clem, Lor, and Ram and at 538 nm for Los with excitation at 477 and 452 nm for Clem and Lor, respectively, and 460 nm for both Los and Ram. The fluorescence intensity was directly proportional to the drug concentration over the ranges 0.05-0.5, 5-20, 1-6, and 2-15 microg/mL for Clem, Lor, Los, and Ram, respectively. The methods were successfully applied for the determination of the studied drugs in pharmaceutical dosage forms with excellent recovery.

Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC-HRMS for assessing medication adherence.

The use of dried blood spot (DBS) collection cards was investigated for the quantification of three therapeutic drugs used in cardiovascular therapy for assessing medication adherence. A liquid chromatography-high resolution mass spectrometry (LC-HRMS) method was developed and validated for the determination of bisoprolol, ramipril and simvastatin. Whole blood spiked with target analytes was used to produce 30 µl blood spots on specimen collection cards. An 8mm disc was cut from the dried blood spot and extracted using methanol: water (70:30, v/v) containing the internal standard, atenolol. Extracts were vortexed, sonicated and then centrifuged. Gradient chromatographic elution was achieved using a Zorbax Eclipse C18 HD 100 mm × 2.1 mm, 1.8 µm pore size column and a mobile phase flow rate of 0.6 ml/min and the column oven temperature at 40 °C with a run time of 3 min. MS detection was carried out in electrospray positive ion mode for the three target drugs and for the IS. Drug recoveries from spiked blood spots were ≥ 92% for bisoprolol and ramipril and ~43% for simvastatin and the drugs were stable in DBS for at least 12 weeks. Validation of the LC-HRMS method showed good linearity and the accuracy (relative error) and precision (coefficient of variation) values were within the pre-defined limits of ≤ 15% at all concentrations. Matrix effects and the effects of different volumes of blood applied to the collection card were investigated. The LC-HRMS method successfully identified control volunteers who were known to be either adherent or non-adherent. There were no false positives from volunteers taking other cardiovascular drugs or from volunteers receiving no medication.

Spectrometric method for the assay of ramipril using molybdophosphoric acid.

UNLABELLED: Ramipril is a drug of the angiotensin converting enzyme inhibitor class. AIM: A new molecular absorbance spectrometric method was developed for the assay of ramipril using molybdophosphoric acid in acidic medium. MATERIAL AND METHODS: The reaction product showed a maximum absorbance at 361 nm. The optimum conditions of the reaction were established. The developed method was validated. RESULTS: The method showed a good linearity in the range of 8 - 36 microg/ml (correlation coefficient r = 0.9996). The detection limit (LD) was 0.86microg/ml and the quantification limit (LQ) 2.88 pg/ml. Precision and accuracy were determined (RSD = 1.15%); mean recovery was 98.90% in the 97.13-101.03% concentration range. CONCLUSIONS: The proposed method is simple, easy to perform, sensitive, linear, precise, accurate and robust.

Simultaneous estimation of ramipril, acetylsalicylic acid and atorvastatin calcium by chemometrics assisted UV-spectrophotometric method in capsules.

In the present work, three different spectrophotometric methods for simultaneous estimation of ramipril, aspirin and atorvastatin calcium in raw materials and in formulations are described. Overlapped data was quantitatively resolved by using chemometric methods, viz. inverse least squares (ILS), principal component regression (PCR) and partial least squares (PLS). Calibrations were constructed using the absorption data matrix corresponding to the concentration data matrix. The linearity range was found to be 1-5, 10-50 and 2-10 µg mL-1 for ramipril, aspirin and atorvastatin calcium, respectively. The absorbance matrix was obtained by measuring the zero-order absorbance in the wavelength range between 210 and 320 nm. A training set design of the concentration data corresponding to the ramipril, aspirin and atorvastatin calcium mixtures was organized statistically to maximize the information content from the spectra and to minimize the error of multivariate calibrations. By applying the respective algorithms for PLS 1, PCR and ILS to the measured spectra of the calibration set, a suitable model was obtained. This model was selected on the basis of RMSECV and RMSEP values. The same was applied to the prediction set and capsule formulation. Mean recoveries of the commercial formulation set together with the figures of merit (calibration sensitivity, selectivity, limit of detection, limit of quantification and analytical sensitivity) were estimated. Validity of the proposed approaches was successfully assessed for analyses of drugs in the various prepared physical mixtures and formulations.

Development of a capillary electrophoresis method for the assay of ramipril and its impurities: an issue of cis-trans isomerization.

The development of a rapid and selective capillary electrophoresis method for the quantitation of ramipril and its eight main impurities in pharmaceutical dosage form is described. Ramipril and three of its impurities contain a proline-similar moiety which causes in solution the presence of interconverting cis-trans isomers with respect to the amide bond. The interplay between electrophoretic migration and isomerization may yield the presence of an undesired interconversion zone between the two isomer peaks in the electropherogram, depending on the experimental conditions. Different capillary electrophoresis operative modes and pseudostationary phases were evaluated, both in normal and reverse polarity, in order to find the essential analytical parameters which could make it possible to overcome this issue and thus accurately quantify the analytes. The best results were obtained by using microemulsion electrokinetic chromatography in reverse polarity, where all the compounds which undergo cis-trans interconversion migrate as a single narrow peak. Experimental design led to identification of the following optimised conditions: background electrolyte, microemulsion made by 88.95% of 90 mM phosphate pH 2.5, 1.05% of n-heptane and 10.00% of SDS/n-butanol in 1:2 ratio; voltage, -26 kV; temperature, 17°C. Applying these conditions, the baseline separation of the analytes was obtained in about 10 min. Validation of the method following ICH guidelines was carried out and the procedure was applied to a real sample of ramipril tablets.

A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs.

The present study describes the development of a novel analytical approach that can reduce by 50-fold the consumption of organic solvents in the charge transfer (CT)-based spectrophotometric analysis. The proposed approach employed 96-microwell assay plates for carrying out the reaction. The CT reaction between the electron-donating analyte and electron-accepting reagent was performed in microwells (200-µL of organic solvent) and the color signals were measured with a microwell-plate reader. Optimum conditions for the proposed approach were established for two antihypertensive drugs, namely ramipril (RML) and lisinopril (LSL) as model compounds for the electron-donating analytes, and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as a π-electron acceptor. Under the optimum conditions, Beer's law was obeyed in the concentration range of 6-100 and 6-60 µg mL-1 for RML and LSL, respectively. The limits of detection were 0.97 and 1.10 µg mL-1 for RML and LSL, respectively. The precision of the methods was satisfactory; the values of relative standard deviations did not exceed 1.1 %. The proposed approach was successfully applied to the analysis of pharmaceutical dosage forms with good accuracy and precision. The results were comparable with those of the reported methods. The approach described herein is of great practical value in pharmaceutical analysis because it reduces the exposure of analysts to the toxic effects of organic solvents, lowers the analysis cost by 50-fold, and it has a high throughput property. Although the approach was validated for RML and LSL, the same methodology could be used for any electron-donating analyte for which a CT-reaction can be performed.

Simultaneous determination of atorvastatin calcium and ramipril in capsule dosage forms by high-performance liquid chromatography and high-performance thin layer chromatography.

Two simple and accurate methods to determine atorvastatin calcium and ramipril in capsule dosage forms were developed and validated using HPLC and HPTLC. The HPLC separation was achieved on a Phenomenex Luna C18 column (250 x 4.6 mm id, 5 microm) in the isocratic mode using 0.1% phosphoric acid-acetonitrile (38 + 62, v/v), pH 3.5 +/- 0.05, mobile phase at a flow rate of 1 ml/min. The retention times were 6.42 and 2.86 min for atorvastatin calcium and ramipril, respectively. Quantification was achieved with a photodiode array detector set at 210 nm over the concentration range of 0.5-5 microg/mL for each, with mean recoveries (at three concentration levels) of 100.06 +/- 0.49% and 99.95 +/- 0.63% RSD for atorvastatin calcium and ramipril, respectively. The HPTLC separation was achieved on silica gel 60 F254 HPTLC plates using methanol-benzene-glacial acetic acid (19.6 + 80.0 + 0.4, v/v/v) as the mobile phase. The Rf values were 0.40 and 0.20 for atorvastatin calcium and ramipril, respectively. Quantification was achieved with UV densitometry at 210 nm over the concentration range of 50-500 ng/spot for each, with mean recoveries (at three concentration levels) of 99.98 +/- 0.75% and 99.87 +/- 0.83% RSD for atorvastatin calcium and ramipril, respectively. Both methods were validated according to International Conference on Harmonization guidelines and found to be simple, specific, accurate, precise, and robust. The mean assay percentages for atorvastatin calcium and ramipril were 99.90 and 99.55% for HPLC and 99.91 and 99.47% for HPTLC, respectively. The methods were successfully applied for the determination of atorvastatin calcium and ramipril in capsule dosage forms without any interference from common excipients.

Spectrofluorimetric assessment of Ramipril using optical sensor Samarium ion-doxycycline complex doped in sol-gel matrix.

A new, simple, sensitive and selective spectrofluorimetric method for the determination of Ramipril is developed. The Ramipril can remarkably quench the luminescence intensity of the Sm(3+) ion in Sm(3+)-doxycycline complex at lambda(ex)=375 nm in sol-gel matrix. In the same time the intensity of the emission band of the Ramipril in DMSO at 454 nm is increased due to the energy transfer from the Sm(3+)-doxycycline complex to Ramipril in the excited stated. The quenching of luminescence intensity of Sm(3+)-doxycycline complex doped in the sol-gel matrix and the enhancement of the emission band of Ramipril at 454 nm are directly proportion to the concentration of Ramipril with a dynamic ranges of 3.4x10(-9) - 1.0x10(-7)mol l(-1) and 2.4x10(-9) - 1.0x10(-7)mol l(-1) and detection limits of 6.0x10(-10) and 5.2x10(-10)mol l(-1), respectively.

Spectrophotometric and atomic absorption determination of ramipril, enalapril maleate and fosinopril through ternary complex formation with molybdenum (V)-thiocyanate (Mo(V)-SCN).

Three different sensitive and accurate spectroscopic procedures were developed for the determination of three angiotensin-converting enzyme inhibitors, namely, ramipril, enalapril maleate and fosinopril. The first two spectrophotometric (extractive and non-extractive) procedures were based on ternary complex formation with molybdenum(V) thiocyanate. The formed complex can be determined by extraction with chloroform measured at lambdamax 517 nm Beer's law was obeyed in the concentration range from (10--90 microg ml(-1)) for ramipril and fosinopril and (4--36 microg ml(-1)) for enalapril maleate with molar absorptivity 1.2x10(4), 2x10(4) and 3.4x10(4) l mol(-1) cm(-1), respectively, or by direct measurement after addition of benzalkonium chloride as surfactant and measuring the formed ternary complex at lambdamax 545 nm with a linear relationship in the concentration range from (8-7-2 microg ml(-1)), (3--27 microg ml(-1)) and (8--72 microg ml(-1)) for ramipril, enalapril maleate and fosinopril with molar absorptivity 1.5x10(4), 5x10(4) and 2.1x10(4) l mol(-1) cm(-1), respectively. The third procedure is atomic absorption measurement through the quantitative determination of molybdenum content of the complex. These methods hold their accuracy and precision well when applied to the determination of ramipril, enalapril maleate and fosinopril in their dosage forms.

Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.

A number of analytical methods were reported for the estimation of atorvastatin and ramipril from their individual dosage forms or in combination with other drugs (Valiyare, 2004; Vachareau and Neirinck, 2000). Here successful reverse phase-high performance liquid chromatographic method and spectroscopic methods developed then validated for the analysis of combined dosage form of atorvastatin and ramipril. Individual lambda-max for atorvastatin is 247 n.m and that of ramipril is 208 n.m. They intercept at 215 n.m which is fixed as wavelength for reverse phase-high performance liquid chromatographic method.

Spectrophotometric and spectrofluorimetric methods for the determination of ramipril in its pure and dosage form.

This paper describes three sensitive spectrophotometric and spectrofluorimetric methods for determination of ramipril in its pure form and pharmaceutical tablets. The first method is based on the oxidation of the drug with 1-chlorobenzotriazole reagent (CBT) in strong alkaline medium followed by measuring the absorbance at 350 nm. The method obeys Beer's law over concentration range 15-50 microg ml(-1). For the second and third, both are non-extractive methods based on the formation of ternary complex between copper (II), eosin and ramipril in the presence of methylcellulose as surfactant. Spectrophotometrically, under the optimum condition, the ternary complex showed an absorption maximum at 543 nm. The method obeys Beer's law over concentration range of 20-80 microg ml(-1). A fluorescence quenching method for the determination of ramipril by forming this ternary complex was also investigated for the propose of enhance the sensitivity of the determination. The methods are simple, sensitive, and accurate. The results obtained are reproducible with a coefficient of variation less than 2%. The proposed have been successfully applied to the assay of ramipril in tablets. The results compare favorably with official method.

Liquid chromatographic separation and UV determination of certain antihypertensive agents.

Three antihypertensive agents were extracted and isolated from commercial formulations. These were purified and characterized by melting point, lambdamax and IR. The percentage recovery by extraction process was in the range 81-91%. Active ingredients from binary formulations were separated by RP-HPLC using methanol-water (50:50 v/v) and by TLC using CHCl3-CH3OH (6:1) as mobile phase. Detection was by UV at 210 nm in HPLC, and by iodine vapors in TLC. The solvent conditions from TLC were transferred to open column chromatographic separation. Quantitative determination was carried out using TLC and column chromatography supplemented with UV spectrophotometry. Recovery was in the range 82-93%. Two combination of drugs, viz. amlodipine+ramipril and amlodipine+enalapril, were separated by the three modes of liquid chromatography. The percentage recovery was in the range 80-92% by open column.

Kinetic spectrophotometric method for the determination of ramipril in pharmaceutical formulations.

The objective of this research was to develop a kinetic spectrophotometric method for determination of ramipril in pure form and pharmaceutical formulations. The method was based on the reaction of carboxylic acid group of the drug with a mixture of potassium iodate (KIO3) and potassium iodide (KI) in aqueous medium at room temperature. The reaction is followed spectrophotometrically by measuring the increase in absorbance at 352 nm as a function of time. The initial-rate and fixed-time methods were adopted for constructing the calibration curves. Both the calibration curves were linear in the concentration range of 10.0-70.0 microg mL(-1). The detection limits were 0.02 microg mL(-1) and 0.15-microg mL(-1) for initial rate and fixed time methods, respectively. The proposed methods are validated statistically and through recovery studies. The point and interval hypothesis tests have been performed confirming that there is no significant difference between the proposed methods and the reference method. The experimental true bias of all samples is less than +/- 2%. The methods have been successfully applied to the determination of ramipril in tablets and capsules.

Some fundamental and technical aspects of the quantitative analysis of pharmaceutical drugs by matrix-assisted laser desorption/ionization mass spectrometry.

The purpose of the present paper was to study some of the underlying physical and technical aspects of high-throughput quantitative matrix-assisted laser desorption/ionization (MALDI) of small drug molecules. A prototype MALDI-triple quadrupole instrument equipped with a high repetition rate laser was employed. Initially, the detection limits and dynamic ranges for the quantitation of four drugs (quinidine, danofloxacin, ramipril and nadolol) were determined. Internal standards were carefully chosen for each of these analytes in terms of structure similarity and fragmentation pathways. Three organic matrices were tested for these assays, resulting in different crystallization behaviors and measurement reproducibilities. alpha-Cyano-4-hydroxycinnamic acid yielded the best results and was subsequently employed for the quantitative determination of all four analytes. Further experiments considered the role of laser energy and pulse rate on the ablated areas as well as ion signals. Light microscope and scanning electron microscope images allowed the examination of the ablated area of the MALDI spots. The images showed convincing evidence that the ablated area was virtually void of crystals after analysis, with no preferential removal of material in the center of the laser's path. Average values for the amount of material ablated were determined to be 3.9+/-0.5% of the total spot size, and as low as 19.5 attomoles of analyte were detectable for our most sensitive analyte, ramipril. It was calculated that, under these assay conditions, it was possible to accurately quantify less than 1 femtomole of all analytes with the use of appropriately pure internal standards. These studies showed very promising results for the quantitative nature of MALDI for small molecules with molecular weights less than 500 Da.

Stability of ramipril in the solvents of different pH.

The stability of ramipril in the buffer solution with different pH and the influence of acid, alkaline and oxidative medium on ramipril stability were studied. The ramipril degradation products were determined by high-performance liquid chromatography (HPLC) method. Acetonitrile:sodium perchlorate was used as the mobile phase, at a flow rate of 1.0 ml/min (linear gradient elution). A Nucleosil 100-S 5 microm C18, 250 mm x 4.6 mm i.d. was utilized as stationary phase. Detection was affected spectrophotometrically at 210 nm. The drug substance was dissolved in the ammonium phosphate buffer (pH 3, 5 and 8) and these solutions were stored at 90 degrees C for 1 h. The other series of test solutions were prepared from stock solution (drug substance dissolved in solvent A of the mobile phase) by dilution in acid (0.1M HCl), alkaline (0.1M NaOH) and oxidative (hydrogen peroxide solution) medium. More then 0.2% of impurity D (ramipril-diketopiperazine) was detected in the buffer of pH 3 and pH 5. In the buffer of pH 8 there was detected more then 1% of impurity E (ramipril-diacid). No peaks for degradation products appeared in the chromatograms above limit of quantification. The alkaline medium has the greatest effect on degradation of ramipril into impurity E (more than 50%).

On-line assay of the S-enantiomers of enalapril, ramipril and pentopril using a sequential injection analysis/amperometric biosensor system.

A sequential injection analysis/amperometric biosensor system is proposed for the enantioselective analysis of the S-enantiomer of enalapril, ramipril and pentopril. The amperometric biosensor used as detector in the sequential injection analysis was designed by immobilization of l-amino acid oxidase in carbon paste. The proposed SIA system can be utilized reliably for the enantioanalysis of the S-enantiomer from the raw materials as well as from their pharmaceutical formulations, with a rate of 75 samples per hour and R.S.D. values better than 0.1% (n = 10).

Square wave voltammetric determination of the angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations.

The angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril are reduced at a hanging mercury drop electrode in the pH range 3.5-13 using Britton-Robinson buffers as supporting electrolyte and KCl as ionic medium. Square wave voltammetry has proved to be the most suitable electroanalytical technique for the quantitative voltammetric determination of these antihypertensive drugs. Optimisation of the chemical and instrumental variables was carried out. Analyses were performed in 0.02 M borate buffer at pH 9.5 and 0.5 M KCl as ionic medium, using a pulse amplitude of 50 mV and a frequency of 150 Hz. A linear relationship between peak current and concentration was found in the interval 0.5-8 microg/ml for cilazapril and up to 6 microg/ml for quinapril and ramipril, allowing the direct determination of their pharmaceutical formulations alone or mixed with hydrochlorothiazide. Good accuracy and repeatativity were obtained.

Spectrophotometric and AAS determination of ramipril and enalapril through ternary complex formation.

Two sensitive, spectrophotometric and atomic absorption spectrometric procedures are developed for the determination of two antihypertensive agents (enalapril maleate and ramipril). The spectrophotometric procedures for the two cited drugs are based on ternary complex formation. The first ternary complex (copper(II), eosin, and enalapril) was estimated by two methods; the first depends on its extraction with chloroform measuring at 533.4 nm. Beer's law was obeyed in concentration range from 56 to 112 microg ml(-1). The second method for the same complex depends on its direct measurement after addition of methylcellulose as surfactant at the pH value 5 at 558.8 nm. The concentration range is from 19 to 32 microg ml(-1). The second ternary complex (iron(III), thiocyanate, and ramipril) was extracted with methylene chloride, measuring at 436.6 nm, with a concentration range 60-132 microg ml(-1). The direct atomic absorption spectrometric method through the quantitative determination of copper or iron content of the complex was also investigated for the purpose of enhancing the sensitivity of the determination. The spectrophotometric and atomic absorption spectrometric procedures hold their accuracy and precision well when applied to the determination of ramipril and enalapril dosage forms.

Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma.

Ramipril, as a secondary amine compound, reacts with 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) producing the corresponding fluorescent NBD-ramipril. According to this fact, spectrophotometric and fluorimetric methods for the determination of ramipril were developed. The effect of these parameters on the reaction product were carefully studied to optimize reaction conditions. The relationship between the absorbance at 465 nm and the concentration was found to be linear over the range 1-10 microg/ml. Moreover, the fluorescence intensity was also found to be directly proportional at the concentration over the range of 20-100 ng/ml at 530 nm after excitation at 465 nm. The proposed procedure was successfully applied to the determination of ramipril in both tablet dosage form and in plasma. Spectrophotometric determination of ramipril tablets yielded a percentage recovery of 98.66+/-0.38, while the percentage recovery of spectrofluorimetric determination of ramipril in spiked human plasma was 99.08+/-1.11%. The results obtained are in good agreement with those obtained by the reference method. No interference could be observed from the co-administered drug (hydrochlorothiazines).